EVALUATING LABORATORY PARAMETERS OF COVID-19 CASES WITH UNDERLYING CHRONIC DISEASES

Yıl 2021, Cilt: 84 Sayı: 2, 158 - 164, 25.04.2021

Muhammed Emin Demirkol , Musa Kaya Süleyman Özsarı , Emine Özsarı

https://doi.org/10.26650/IUITFD.2020.0101

Öz

Objective: COVID-19 infection caused by the SARS-CoV-2 which was initially detected in China during the last days of 2019 has spread to the whole world in a short period of time causing a pandemic with devastating results. In performing this study, we aimed to reveal the differences in laboratory findings of COVID-19 cases accompanied by chronic diseases compared to the cases without any pre-existing medical condition. Methods: This is a retrospective cross-sectional study and consists of 226 patients diagnosed with COVID-19 who applied to health institutions in Bolu, Turkey between 11.03.2020 and 26.05.2020. Results: The mean age of the patients included in the study was 61.95±16.82 (min: 32-max: 93), 126 (55.8%) of the patients were women and 100 (44.2%) were men. Seventy-five (33.2%) had at least one chronic disease. The most prevalent comorbid diseases in our patients were found to be hypertension (15.9%), chronic obstructive pulmonary disease (14.6%) and diabetes mellitus (9.7%). Findings such as leukocytosis, basophilia and neutrophilia, elevated CRP, elevated D-DIMER and elevated LDH, which are relatively common in COVID-19 cases, were more extensive in cases accompanied by underlying diseases. Conclusion: Impaired laboratory findings of COVID-19 patients with concomitant chronic diseases are more severe than the group without additional disease. We recommend that there can be more studies in which all parameters that may affect the results are evaluated

Anahtar Kelimeler

COVID-19, chronic diseases, laboratory findings

KRONİK HASTALIĞI OLAN COVİD-19 VAKALARININ LABORATUVAR PARAMETRELERİNİN DEĞERLENDİRİLMESİ

Öz

Amaç: 2019 yılının son günlerinde ilk olarak Çin’de tespit edilen SARS-CoV-2 (Yeni Tip Coronavirüs) virüsünün sebep olduğu COVID-19 enfeksiyonu kısa bir zaman diliminde, bütün dünyaya yayılarak yıkıcı sonuçlara sebep veren pandemiye yol açmıştır. Bu çalışma ile kronik hastalığı olan COVID-19 vakalarının eşlik eden herhangi bir hastalığı olmayan vakalara kıyasla laboratuvar bulgularındaki farklılıkları ortaya koymayı amaçladık. Gereç ve Yöntem: Bu çalışma kesitsel tipte retrospektif özellikte olup 11.03.2020 ve 26.05.2020 tarihleri arasında Bolu’daki sağlık kurumlarına başvurup COVID-19 tanısı almış 226 hastadan oluşmaktadır. Bulgular: Çalışmaya dahil edilen 226 hastanın yaş ortalamasının 61,95±16,82 olduğu (min:32-mak:93); 126’sı (%55,8) kadın, 100’ü (%44,2) erkek hasta olup, 75 (%33,2)’inin kronik hastalığı olduğu saptanmıştır. Hastalarımızda en sık görülen komorbid hastalıkların hipertansiyon (%15,9), kronik obstrüktif akciğer hastalığı (%14,6) ve diabetes mellitus (%9,7) olduğu görüldü. COVID-19 vakalarında sık olarak rastlanan lökositoz, nötrofili ve bazofilinin; ayrıca CRP, LDH ve D-DİMER yüksekliğinin, komorbid hastalığı olan vakalarda olmayanlara göre daha yaygın olduğu saptanmıştır. Sonuç: Eşlik eden kronik hastalıkları olan COVID-19 hastalarına ait bozulmuş laboratuvar bulguları ek hastalığı olmayan gruba göre daha ciddi seyretmektedir. Sonuçları etkileyebilecek tüm parametrelerin değerlendirildiği yeni çalışmalara ihtiyaç vardır.

Anahtar Kelimeler

COVID-19, kronik hastalıklar, laboratuvar bulguları

Kaynakça

• 1. Wu Z, Mc Googan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020;323(13):1239-42. [Epub ahead of print] [CrossRef]
• 2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-13. [CrossRef]
• 3. Guan WJ, Ni ZY, Hu Y. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020 [Epub ahead of print] [CrossRef]
• 4. Yang R, Gui X, Zhang Y, Xiong Y. The role of essential organ-based comorbidities in the prognosis of COVID-19 infection patients. Expert Rev Respir Med 2020;1-4. [Epub ahead of print] [CrossRef]
• 5. Nandy K, Salunke A, Pathak SK, et al. Coronavirus disease (COVID-19): A systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events. Diabetes Metab Syndr 2020;14(5):1017-25. [Epub ahead of print] [CrossRef]
• 6. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et all. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497-506. [CrossRef]
• 7. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020;180(7):934-43. [Epub ahead of print] [CrossRef]
• 8. Zhang J, Wu J, Sun X, et al. Association of hypertension with these verity and fatality of SARS-CoV-2 infection: A meta-analysis. Epidemiol Infect 2020;148:e106. Published online 2020 May 28. [Epub ahead of print] [CrossRef]
• 9. Wu ZH, Tang Y, Cheng Q. Diabetes increases the mortality of patients with COVID-19: a meta-analysis .Acta Diabetol. 2020: 1–6. [Epub ahead of print] [CrossRef]
• 10. Alqahtani JS, Oyelade T, Aldhahir AM, et al. Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. PLoSOne 2020;15(5):e0233147. [CrossRef]
• 11. Venkatesulu BP, Chandrasekar VT, Girdhar P, et al. A systematic review and meta-analysis of cancer patients affected by a novel coronavirus. medRxiv. Preprint 2020 May 29. [Epub ahead of print] [CrossRef]
• 12. Pranata R, Huang I, Lim MA, Wahjoepramono PEJ, July J. Impact of Cerebrovascular and Cardiovascular Diseases on Mortality and Severity of COVID-19 – Systematic Review, Meta-analysis, and Meta-regression. J Stroke Cerebrovasc Dis 2020;29(8):104949. Published online 2020 May 14. [Epub ahead of print] [CrossRef]
• 13. Yang R, Gui X, Zhang Y, Xiong Y. The role of essential organbased comorbidities in the prognosis of COVID-19 infection patients. Expert Rev Respir Med 2020:1-4.Published online 2020 Apr 28. [Epub ahead of print] [CrossRef]
• 14. Ferrari D, Motta A, Strollo M, Banfi G, Locatelli M. Routine blood tests as a potential diagnostic tool for COVID-19. Clin Chem Lab Med 2020;58(7):1095-9. [CrossRef]
• 15. Zhang L, Yan X, Fan Q, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost 2020;18(6):1324-9. [CrossRef]
• 16. Ambrosino I, Barbagelata E, Ruggieri A, Massiah G ,Giannico O, Politi C, et al. Gender differences in patients with COVID-19: a narrative review. Monaldi Archives for Chest Disease 2020;90:138. [Epub ahead of print] [CrossRef]
• 17. Gemmati D, Bramanti B, Serino ML, Secchiero P, Zauli G. COVID-19 and Individual Genetic Susceptibility / Receptivity: Role of ACE1/ACE2 Genes, Immunity, Inflammation and Coagulation. Might the Double X-chromosome in Females Be Protective against SARS-CoV-2 Compared to the Single X- Chromosome in Males?. Int J Mol Sci 2020;21(10);3474. [CrossRef]
• 18. Gargaglioni LH, Marques DA. Let’s talk about sex in the context of COVID-19. J Appl Physiol 2020;128(6):1533-8. [Epub ahead of print] [CrossRef]
• 19. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ 2020;11(1):29. [Epub ahead of print] [CrossRef]
• 20. Neha C, Tsering P, Kavita S, Rahul K, Brian B, Qadar P. Sexderived attributes contributing to SARS-CoV-2 mortality. Am J Physiol Endocrinol Metab 2020;319(3):E562-7. [Epub ahead of print] [CrossRef]